Cover Image

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer

Saved in:

Bibliographic Details
Main Authors:	Ioannis Alagkiozidis (Author), Melissa Lozano (Author), Mithun Devraj (Author), Yi-Chun Lee (Author), Ovadia Abulafia (Author)
Format:	Book
Published:	Elsevier, 2015-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
by: Rose Isono-Nakata, et al.
Published: (2018)

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
by: Roze Isono-Taniguchi, et al.
Published: (2022)

Metronomic therapy for gynecologic cancers
by: Wen-Hsiang Su, et al.
Published: (2012)

Clinical Applications of Metronomic Chemotherapy
Published: (2023)

Metronomics: Intrinsic Anakoinosis Modulator?
by: André Nicolas, et al.
Published: (2018)

Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series
by: Shannon M. Glynn, et al.
Published: (2024)

Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives
by: Vijay Kumar Panthi, et al.
Published: (2023)

Oral metronomic therapy in head and neck cancer
by: Vinod Sharma, et al.
Published: (2021)

Oral metronomic therapy in head and neck cancer
by: Raja Pramanik, et al.
Published: (2021)

Oral uracil and tegafur as postoperative adjuvant metronomic chemotherapy in patients with advanced oral squamous cell carcinoma
by: Jiun-Sheng Lin, et al.
Published: (2015)

A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability
by: Daniela Chirio, et al.
Published: (2021)

Oral metronomic therapy in head and neck cancer - Authors' reply
by: Vijay Patil, et al.
Published: (2021)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
by: Ruby Maharjan, et al.
Published: (2019)

The metronome-based methodology to monitor the stroke length changes in trained swimmers
by: Marco Fassone, et al.
Published: (2023)

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
by: Samantha Cohen, et al.
Published: (2019)

PENGGUNAAN METRONOM LAMPU UNTUK MENINGKATKAN KOORDINASI GERAK TARI SISWA TUNARUNGU
by: Tupan, Noviardi
Published: (2014)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015)

Downstaging with atezolizumab-bevacizumab: a case series
by: Anand V. Kulkarni, et al.
Published: (2024)

The use of a metronome during cardiopulmonary resuscitation in the emergency room of a university hospital
by: Renata Maria de Oliveira Botelho, et al.

Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia
by: Dean G. Campelj, et al.
Published: (2021)

Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable?
by: Klag N, et al.
Published: (2016)

Breast metastases: A rare manifestation of advanced uterine serous carcinoma
by: Jennifer McEachron, et al.
Published: (2019)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020)

Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity
by: Ruby Maharjan, et al.
Published: (2021)

Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients
by: Soshi Kusunoki, et al.
Published: (2018)

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis
by: Wanjun Tao, et al.
Published: (2020)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
by: Shu-Ping Lee, et al.
Published: (2019)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023)

Bevacizumab-Induced Geographic Tongue
by: Marta Martinez-Garcia, et al.
Published: (2021)

Monitoring antiangiogenesis of bevacizumab in zebrafish
by: Zhang J, et al.
Published: (2018)

Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
by: Taraswi Mitra Ghosh, et al.
Published: (2021)

Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells
by: Yamila Sanchez, et al.
Published: (2024)

A One Session Gait Retraining Protocol with Metronome Augmentation Increases Cadence in Novice and Recreational Runners
by: Angie Huber, et al.
Published: (2024)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020)

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide
by: Sandi L. Navarro, et al.
Published: (2022)

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
by: Lister J, et al.
Published: (2012)

Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
by: Suemin Park, et al.
Published: (2024)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
by: Chun-Hua Zhou, et al.
Published: (2021)